February 16, 2022
Video
Julie Renee Brahmer, MD, MSc, discusses the issues with using tyrosine kinase inhibitors and immunotherapy in patients with locally advanced non–small cell lung cancer.
February 07, 2022
Video
Julie Renee Brahmer, MD, MSc, discusses upcoming and recent trials that may change the sequencing of targeted therapies in patients with locally advanced non–small cell lung cancer.
March 20, 2020
Video
Julie R. Brahmer, MD, discusses the circumstances in which a physician can choose osimertinib over other EGFR tyrosine kinase inhibitors for patients with EGFR-mutant lung cancer.
March 06, 2020
Video
Julie R. Brahmer, MD, discusses the role of molecular testing for patients with lung cancer and why this is particularly important for those with early-stage disease.
November 14, 2019
Article
Although immune checkpoint inhibitor therapy has represented a paradigm shift in the treatment of multiple types of cancer, many patients’ cancers do not respond at all to these therapies or develop resistance after an initial period of response, according to Julie R. Brahmer, MD.
March 11, 2019
Video
Julie R. Brahmer, MD, discusses data for atezolizumab plus platinum/etoposide versus platinum/etoposide alone in patients with small cell lung cancer in the IMpower133 trial.